Alendrate

Country: Նոր Զելանդիա

language: անգլերեն

source: Medsafe (Medicines Safety Authority)

active_ingredient:

Alendronate sodium trihydrate 13.05mg Equivalent to 10 mg alendronic acid;  

MAH:

Viatris Limited

INN:

Alendronate sodium trihydrate 13.05 mg (Equivalent to 10 mg alendronic acid)

dosage:

10 mg

pharmaceutical_form:

Tablet

composition:

Active: Alendronate sodium trihydrate 13.05mg Equivalent to 10 mg alendronic acid   Excipient: Croscarmellose sodium Lactose monohydrate Magnesium stearate Microcrystalline cellulose Povidone

units_in_package:

Blister pack, PVC/aluminium, 30 tablets

class:

Prescription

prescription_type:

Prescription

manufactured_by:

Pharmaceutical Works Polpharma SA

therapeutic_indication:

Alendrate is indicated: · In postmenopausal women for the treatment of osteoporosis to prevent fractures, including those of the hip and spine (vertebral compression fractures). · In postmenopausal women who are at risk of developing osteoporosis Alendrate is indicated for the prevention of osteoporosis to reduce the risk of future fracture. · For the treatment of osteoporosis in men to prevent fractures. · For the treatment and prevention of glucocorticoid-induced osteoporosis in men, premenopausal women and postmenopausal women receiving oestrogen. · For treatment of Paget's disease of bone in men and women.

leaflet_short:

Package - Contents - Shelf Life: Blister pack, PVC/aluminium - 30 tablets - 36 months from date of manufacture stored at or below 25°C

authorization_date:

2004-04-19